Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality

Area of Science:

• Genetics
• Molecular Biology
• Muscle Physiology

Background:

• Myostatin, a TGF-beta family member, negatively regulates skeletal muscle mass.
• Reducing myostatin is a potential therapeutic strategy for muscle degenerative diseases like muscular dystrophy.
• Laminin-deficient congenital muscular dystrophy represents a severe form of muscular dystrophy.

Purpose of the Study:

• To investigate the effects of myostatin elimination on laminin-deficient congenital muscular dystrophy.
• To determine if blocking myostatin can ameliorate the dystrophic phenotype in laminin-deficient mice.

Main Methods:

• Crossed dy(W) laminin alpha2-deficient mice with myostatin null mice to create double-deficient dy(W)/dy(W);Mstn(-/-) mice.
• Assessed clinical phenotype, muscle regeneration, degeneration, inflammation, and mortality in the resulting mouse models.

Main Results:

• Double-deficient mice exhibited a severe phenotype, similar to laminin-deficient mice, despite increased muscle regeneration.
• Muscle degeneration and inflammation were not alleviated by myostatin elimination.
• Absence of myostatin led to significantly reduced brown and white fat, increasing pre-weaning mortality.

Conclusions:

• Myostatin elimination promotes muscle formation but impairs fat development in laminin-deficient models.
• Blocking myostatin does not reduce muscle pathology and may lead to adverse effects, such as reduced adiposity.
• Therapeutic strategies targeting myostatin for muscular dystrophy require careful consideration of potential side effects.